Tarsius Pharma, a late clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, today announced the Company is chaging its name and logo to Tarsier Pharma, effective immediately. Management of the company and staff remain the same.
“While our name has changed, we remain steadfast in our passion and commitment in achieving our goals. We eagerly anticipate 2021 and look forward to a year filled with meaningful milestones” said Ruth Friedel, Business Development Manger at Tarsier Pharma. “Interestingly, Tarsier is a cute primate, an animal blessed with fantastic eyesight and visual capababilites due to is enormous eyes.”
About Tarsier Pharma
Tarsier Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.
The company’s investors include a wholly-owned subsidiary company of Sun Pharmaceutical Industries Limited, BioLight Life Sciences Ltd, as well as private investors and family offices. The company has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.
For more information, please contact: